产品
编 号：F136654
分子式：C15H15NO
分子量：225.29
分子式：C15H15NO
分子量：225.29
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1357302-64-7
产品详情
生物活性：
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.
体内研究：
OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.Animal Model:4-week-old BALB/c female mice
Dosage:6, 20, 40 mg/kg
Administration:Intraperitoneal; daily; for 7 days
Result:Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.
体外研究：
OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC50 (IC50: ~10 μM in HeLa cells; IC50: ~3 μM in HFF cells) relative to the control MAOI TCP (IC50: ~1 mM).
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.
体内研究：
OG-L002 (i.p.; 6-40 mg/kg; daily; for 7 days) reduces the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.Animal Model:4-week-old BALB/c female mice
Dosage:6, 20, 40 mg/kg
Administration:Intraperitoneal; daily; for 7 days
Result:Reduced the levels of detectable viral genomes in the ganglia in a dose-dependent manner at both 3 and 5 days postinfection.
体外研究：
OG-L002 inhibits viral IE gene expression in both cells with a significantly reduced IC50 (IC50: ~10 μM in HeLa cells; IC50: ~3 μM in HFF cells) relative to the control MAOI TCP (IC50: ~1 mM).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备